Senti Biosciences Holdings (SNTI) Operating Expenses (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Operating Expenses of $18.7 million for Q4 2025, up 15.41% year-over-year from $16.2 million in Q4 2024, and up 10.09% quarter-over-quarter from $16.9 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Operating Expenses (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Operating Expenses history runs 5 years deep, the most recent figure standing at $18.7 million for Q4 2025.
- In Q4 2025, Operating Expenses rose 15.41% year-over-year to $18.7 million; the TTM figure through Dec 2025 stood at $68.8 million (up 12.72% YoY), while the FY2025 annual figure was $68.8 million, up 12.72% from the prior year.
- Operating Expenses for Q4 2025 stood at $18.7 million, up from $16.9 million in the prior quarter.
- The five-year high for Operating Expenses was $44.2 million in Q3 2023, with the low at $1178.0 in Q1 2021.
- The 5-year median for Operating Expenses is $16.3 million (2023), against an average of $16.4 million.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses jumped 1091750.59% in 2022, then tumbled 65.59% in 2024.
- Senti Biosciences Holdings' Operating Expenses stood at $11.7 million in 2021, then surged by 44.31% to $16.9 million in 2022, then increased by 10.95% to $18.7 million in 2023, then retreated by 13.54% to $16.2 million in 2024, then rose by 15.41% to $18.7 million in 2025.
- Business Quant data shows SNTI's Operating Expenses at $18.7 million in Q4 2025, $16.9 million in Q3 2025, and $16.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 541.02 Mn |
| 10 | Senti Biosciences Holdings | 12.92 Mn | 12.92 Mn | - | 14.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.66 Mn |
| Sep 30, 2025 | 16.95 Mn |
| Jun 30, 2025 | 16.80 Mn |
| Mar 31, 2025 | 16.40 Mn |
| Dec 31, 2024 | 16.17 Mn |
| Sep 30, 2024 | 15.22 Mn |
| Jun 30, 2024 | 13.36 Mn |
| Mar 31, 2024 | 16.30 Mn |
| Dec 31, 2023 | 18.70 Mn |
| Sep 30, 2023 | 44.21 Mn |
| Jun 30, 2023 | 16.13 Mn |
| Mar 31, 2023 | 16.25 Mn |
| Dec 31, 2022 | 16.85 Mn |
| Sep 30, 2022 | 16.51 Mn |
| Jun 30, 2022 | 23.13 Mn |
| Mar 31, 2022 | 12.86 Mn |
| Dec 31, 2021 | 11.68 Mn |
| Sep 30, 2021 | 12.53 Mn |
| Jun 30, 2021 | 9.79 Mn |
| Mar 31, 2021 | 1,178.00 |